Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798218 | 0.79 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1797315 | 0.77 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1799280 | 0.76 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1795874 | 0.76 | LMNA (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1797431 | 0.75 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2822469 | 0.68 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9924116 | 0.68 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAOPRM1OPRD1 | |
| SCHEMBL4569249 | 0.68 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAOPRM1OPRD1 | |
| SCHEMBL9924115 | 0.68 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAOPRM1OPRD1 | |
| SCHEMBL1798088 | 0.68 | DRD2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | claimed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | claimed |
| EP-1730119-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092864-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | claimed |
| US-7795447-B2 | 4-(Acylaminoacetylamino)imidazole derivatives, e.g., methyl 3-(4-{2-[2-(3,5-Difluorophenyl)acetylamino]pentanoylamino}imidazol-1-yl)butyrate; treating neurodegenerative and/or neurological disorders such as Alzheimer's disease and Down's Syndrome | PFIZER INC (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-09-18 | — | — | US | disclosed |
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1730119-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092864-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | PSEN1 2/4885PSEN2 3/4885APH1B 45/4885 |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | PSEN1 2/4885PSEN2 3/4885APH1B 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.